Search
10X Genomics Inc
TXGAdd to Watchlist
63.570USD
-1.480-2.27%
Market hours 11/10, 11:50（ET）
8.28BMarket Cap
LossP/E TTM
10X Genomics Inc (TXG) Stock Price Target & Forecast
Analyst Rating
Based on 17 analysts giving stock ratings to 10X Genomics Inc in the past month.
Buy
5 Strong Buy
2 Buy
10 Hold
0 Sell
0 Strong Sell
Target Price
73.929USD+5.45%
TXG Analyst Recommendation Trends
In the current month, TXG has received 2 Buy Ratings, 10 Hold Ratings, and 0 Sell Ratings. TXG average Analyst price target in the last month is 73.929.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
5
5
4
4
4
4
4
3
2
2
2
2
2
2
2
2
10
11
10
10
11
12
12
13
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
17
18
16
16
17
18
18
18
TXG Analyst Rating for Peer Comparison
Updated: Nov 5, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Stryker Corp
SYK
10
14
6
0
0
30
Dexcom Inc
DXCM
13
12
4
0
0
29
Medtronic PLC
MDT
8
11
10
0
0
29
Guardant Health Inc
GH
12
14
2
0
0
28
Abbott Laboratories
ABT
11
13
4
0
0
28
Medline Ord Shs Class A
MDLN
10
12
6
0
0
28
Zimmer Biomet Holdings Inc
ZBH
2
5
20
0
0
27
Insulet Corp
PODD
7
7
12
0
0
26
Tandem Diabetes Care Inc
TNDM
5
8
10
0
0
23
Repligen Corp
RGEN
5
12
4
0
0
21
Financial Forecasting
Based on analysts' estimates, TXG EPS is projected to reach -0.222 in FY2026Q4, following reported EPS of -0.149 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
FY2027Q1
Forecast
-0.29
-0.24
-0.26
-0.22
-0.16
Actual
-0.10
-0.14
-0.15
--
--
Surprise
+63.99%
+43.36%
+43.35%
--
--
FAQs
What is 10X Genomics Inc's expected revenue for the next quarter?
10X Genomics Inc's expected revenue is 170.36M.
What is 10X Genomics Inc's price target?
Analysts forecast that 10X Genomics Inc's price target is USD 73.93, with the highest forecast at USD 110.00 and the lowest forecast at USD 40.00.
How have 10X Genomics IncTXG's recent earnings per share performed?
The market expectation was USD -0.15, while 10X Genomics IncTXG's earnings per share (EPS) for the previous quarter was USD -0.14. EPS for the next quarter is expected at USD -0.22.
What is the analyst rating for 10X Genomics Inc?
Based on the ratings of 10X Genomics Inc's stock from 17 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.